UB
NBIX icon

UMB Bank’s Neurocrine Biosciences NBIX Stock Holding History

UMB Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$172K Buy
1,306
+71
+6% +$9.42K ﹤0.01% 739
2025
Q4 		$175K Buy
1,235
+115
+10% +$16.7K ﹤0.01% 712
2025
Q3 		$157K Buy
1,120
+63
+6% +$8.54K ﹤0.01% 691
2025
Q2 		$133K Buy
1,057
+161
+18% +$18.5K ﹤0.01% 725
2025
Q1 		$99.1K Buy
896
+441
+97% +$55.9K ﹤0.01% 764
2024
Q4 		$62.1K Buy
455
+309
+212% +$38.2K ﹤0.01% 829
2024
Q3 		$16.8K Buy
146
+84
+135% +$11.5K ﹤0.01% 1296
2024
Q2 		$8.54K Buy
62
+38
+158% +$5.21K ﹤0.01% 1299
2024
Q1 		$3.31K Buy
+24
New +$3.28K ﹤0.01% 1426
2023
Q4 		– Sell
-2
Closed -$225 – 1698
2023
Q3 		$225 Hold
2
– – ﹤0.01% 1665
2023
Q2 		$189 Buy
+2
New +$195 ﹤0.01% 1655
2022
Q1 		– Sell
-36
Closed -$3K – 2040
2021
Q4 		$3K Buy
+36
New +$3.31K ﹤0.01% 1750

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UMB Bank's NBIX Position: Q1 2026 in Review

UMB Bank increased its Neurocrine Biosciences (NBIX) stake by 5.7% in Q1 2026, buying an estimated $9.42K and bringing the position to 1,306 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #739.

UMB Bank first reported a position in NBIX in Q4 2021 and has held it in 12 quarters since. The position peaked at $175K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • UMB Bank held 1,306 shares of Neurocrine Biosciences worth $172K as of Q1 2026.
  • UMB Bank bought 71 Neurocrine Biosciences shares in Q1 2026, an estimated $9.42K.
  • Neurocrine Biosciences made up ﹤0.01% of UMB Bank's portfolio in Q1 2026, its #739 holding.
  • UMB Bank first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 12 quarters since.
  • UMB Bank's Neurocrine Biosciences position peaked at $175K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on UMB Bank's 13F filing for Q1 2026, filed 11 May 2026.